A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507311-35-00

Acronym

CUV052

Enrollment

Registered

2024-02-20

Start date

2024-03-07

Completion date

2025-01-20

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythropoietic Protoporphyria (EPP)

Brief summary

Cmax, AUC(0-t)

Interventions

DRUGSCENESSE 16 mg implant

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Cmax, AUC(0-t)	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026